New pill shows promise for tough psoriasis cases
NCT ID NCT07233291
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an oral medication called roflumilast in 36 adults with moderate-to-severe plaque psoriasis. Over 12 weeks, researchers will measure how much the skin improves and check for side effects. The goal is to see if this drug can help reduce symptoms like redness, scaling, and itching.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS (PSO) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mansoura University Hospital
RECRUITINGAl Mansurah, Dakahlia Governorate, 35511, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common blood thinner shield psoriasis Patients' arteries?
- Can a new pill tame psoriasis? early safety trial begins
- Psoriasis patients: does your injection schedule matter?
- New psoriasis cream takes on old standby in Head-to-Head trial
- World's largest psoriasis care study launches to uncover treatment gaps
- Fasting diet shows promise for psoriasis relief